Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated Interferon Beta-1a (BIIB017) in Relapsing Multiple Sclerosis
2008-006333-27Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing PEGylated interferon beta-1a with Placebo (2 arms). Primary endpoint: Annualized relapse rate at 1 year. Started Apr 2009; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-006333-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006333-27.